FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549	

wasiiiigtoii,	D.C. 20049	

OMB APPRO	OVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Koenig Sheldon L.</u>						2. Issuer Name and Ticker or Trading Symbol Esperion Therapeutics, Inc. [ESPR]								heck all	ship of Reporti applicable) irector		10% O	wner
(Last) C/O ESP	(Fi	rst) (MIERAPEUTICS,	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/17/2023									fficer (give title elow) Presiden		Other (below)	specify	
					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicabline)				
(Street) ANN AF	RBOR M	I 4	8108											F	Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of	1. Title of Security (Instr. 3) 2. Transact Date (Month/Date)			Execution Date,		Date,	3. Transaction Code (Instr. 8) 4. Securities Acc Disposed Of (D) 5)						5. Amount of Securities Beneficially Owned Following Reported		n: Direct	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) or (D) Pri		Tra	nsaction(s) str. 3 and 4)			(Instr. 4)			
Common Stock 03/17/2					2023				S		6,999(1)	D	\$1.7	783	292,816		D	
		Tal									osed of, o				ned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	4. Transa Code (8)		5. Nu of Deriv Secul Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4) Amou or Numb of Title Share		8. Price Derivati Security (Instr. 5	ve derivative Securities	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

Remarks:

/s/ Sheldon L. Koenig

03/20/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} Shares were sold to satisfy tax obligation on vested shares of restricted stock units.